Patent Application
20170029474
This application claims the benefit of priority to Japanese Patent Application No. 2014-008675, filed on Jan. 21, 2014, the entire contents of which are incorporated by reference herein.
Technical Field
The present invention relates to a polypeptide and an antitumor agent.
Background Art
HB-EGF is a heparin-binding growth factor. Growth factors of the EGF family include not only HB-EGF, but also EGF, transforming growth factor (TGF-α), amphiregulin (AR), epiregulin, and the like. These molecules bind to the EGF receptor and its family (ErbB family) molecules to promote the phosphorylation of the receptor. More specifically, HB-EGF binds to EGF receptors ErbB1 and ErbB4. HB-EGF is expressed in various tissues, and high expression of the mRNA is observed in the lung, skeletal muscle, and heart. Further, it has been reported that HB-EGF is highly expressed in various cancer tissues and sites of inflammation. There are reports that HB-EGF greatly promotes growth of fibroblasts, smooth muscle cells, or keratinocytes. It has also been reported that HB-EGF plays an important role in the morphogenesis and regeneration of organisms as well as being intimately involved in the growth, invasion, metastasis, and anti-cancer drug resistance of cancer cells. HB-EGF is synthesized as a membrane-anchored molecule (proHB-EGF) on the cell membrane and cleaved by protease on the cell surface to yield soluble HB-EGF (sHB-EGF). This sHB-EGF mainly serves as a growth factor, but there is also a report that proHB-EGF acts as a growth factor in a membrane-anchored form (Non-patent Literature 1 to 3).
Diphtheria toxin (DT), which is produced by Corynebacterium diphtheriae, is a 535-amino-acid protein with a molecular weight of about 58.4 kDa. DT is composed of fragment A and fragment B. Conformationally, DT includes a catalytic domain (C domain), a transmembrane domain (T domain), and a receptor binding domain (R domain). Fragment A corresponds to the C domain, and fragment B is composed of T and R domains (
CRM197 (Cross reaction material) has G52E mutation in DT. This mutation inactivates the ADP-ribosylation activity, thus causing toxicity as DT to be lost; however, since CRM197 has the same R domain as that of DT, it binds to proHB-EGF in the same manner as DT. The R domain of DT and the R domain of CRM197 bind to the EGF-like domain of proHB-EGF. Therefore, DT and CRM197 bind to sHB-EGF, as well. Once DT or CRM197 binds to sHB-EGF, the sHB-EGF cannot bind to the EGF receptor, resulting in suppression of the cell growth effect of sHB-EGF. CRM197 can thus be used as an HB-EGF inhibitor (Non-patent Literature 5 and Patent Literature 1 and 2).
Studies are in progress to develop CRM197 as an anti-cancer agent by utilizing the HB-EGF inhibitory effect of CRM197. In nonclinical tests to date, CRM197 is reported to strongly suppress tumorigenesis of human cancer cells inoculated into nude mice, and, furthermore, clinical trials for an anti-cancer agent containing CRM197 as an active ingredient have been performed (Non-patent Literature 6 and 7).
PTL 1: JP2006-232761A
PTL 2: JP2004-155776A
NPL 1: Raab, G. and M. Klagsbrun, Heparin-binding EGF-like growth factor. Biochim Biophys Acta, 1997. 1333 (3): p. F179-99.
NPL 2: Iwamoto, R., at al., Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc Nati Acad Sci USA, 2003. 100 (6): p. 3221-6.
NPL 3: Higashiyama, S., at al., The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor. J Cell Biol, 1995. 128 (5): p. 929-38.
NPL 4: Collier, R. J., Understanding the mode of action of diphtheria toxin: a perspective on progress during the 20th century. Toxicon, 2001.39 (11): p. 1793-803.
NPL 5: Mitamura, T., at al., Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human hepatin-binding. EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. J Biol Chem, 1995. 270 (3): p. 1015-9.
NPL 6: Miyamoto, S., et. al., Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res, 2004. 64 (16): p. 5720-7.
NPL 7: Miyamoto, S., at al., Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy. Cancer Sci, 2006. 97 (5): p. 341-7
An object of the present invention is to provide a polypeptide and an antitumor agent that more strongly inhibit the binding of HB-EGF to the EGF receptor.
The present inventor conducted extensive research on the preparation of a molecule that suppresses the growth factor effect of HB-EGF more strongly than CRM197, and found that the binding between HB-EGF and the EGF receptor can be more strongly inhibited by an amino acid substitution in at least specific position of the R domain of CRM197.
The present invention provides the following polypeptide and antitumor agent.
Item. 1. A polypeptide comprising an R domain of CRM197 and comprising one or more amino acid substitutions at positions selected from the group consisting of 391, 460, 466, 467, 468, 472, 507, and 520 of the R domain.
Item 2. The polypeptide according to Item 1, which comprises one or more amino acid substitutions at positions selected from the group consisting of 391, 460, 466, 467, 468, and 472 of the R domain.
Item 3. The polypeptide according to Item 1 or 2, which comprises at least one member selected from the group consisting of H391K, R460H, G466D, D467A, V468T, R472K, D507N, and H520K in. the R domain of CRM197.
Item. 4. The polypeptide according to any one of Items 1 to 3, wherein the polypeptide is a modified CRM197 comprising a C domain, a T domain, and the R domain of CRM197.
Item 5. An antitumor agent comprising the polypeptide according to any one of Items 1 to 4.
Item 6. The antitumor agent according to Item 5, wherein an antitumor agent is bound to the polypeptide according to any one of Items 1 to 4.
Item 7. A pharmaceutical composition comprising an effective amount of the polypeptide according to any one of Items 1 to 4 and a pharmaceutical carrier.
Item 8. A method for treating a tumor, comprising administering an effective amount of the polypeptide according to any one of Items 1 to 4 to a subject.
Item 9. Use of the polypeptide according to any one of Items 1 to 4 for the production of an antitumor agent.
As used herein, the singular forms “a,” “an,” and. “the” are intended to include the singular and the plural unless otherwise indicated herein or clearly contradicted by context.
As used herein, the amino acids of CRM197 are numbered starting with the amino acid ((Gly)) at position 26 in the amino acid sequence of SEQ ID NO: 1 as number 1, excluding the signal sequence (1 to 25).
In SEQ ID NO: 1, the three domains of CRM197 consist of the following amino acids:
The polypeptide of the present invention comprises one or more amino acid substitutions at positions selected from the group consisting of 391, 460, 466, 467, 468, 472, 507, and 520 of the R domain of CRM197. The preferred positions of substitutions are positions 391, 460, 466, 467, 468, and 472. The most preferred substitutions are H391K, R460H, G466D/D467A/V468T, R472K, D507N, and H520K.
An amino acid substitution at a specific position in the polypeptide comprising the R domain of CRM197 can be introduced by performing site-directed mutagenesis using a. Site-Directed Mutagenesis System Mutan (registered trademark)-Super Express Km kit (TAKARA RIO Inc.) or the like on DNA encoding the polypeptide, or by replacing a specific base by another base with respect to the gene by recombinant PCR (polymerase chain reaction) (PCR protocols, Academic Press, New York, 1990), SOE (splicing by overlap extension)-PCR (Gene, 77, 61, 1989), or the like.
The amino acid sequence of CRM197 is shown in SEQ ID NO: 1, and the DNA sequence encoding CRM197 is shown in SEQ ID NO: 2. Introduction of a mutation, such as a substitution, in the polypeptide can be performed using the DNA. sequence of SEQ ID NO: 2
The site into which such an amino acid substitution mutation is introduced is a site that allows for stronger activity to inhibit the binding between HB-EGF and the EGF receptor than the activity of the wild-type (WT) R domain, into which no mutation is introduced. However, the polypeptide of the present invention also includes mutants further comprising an amino acid substitution or deletion at a position with little or no impact on such inhibitory activity other than the positions above as long as they have inhibitory activity more excellent than the wild-type R domain.
The polypeptide of the present invention comprises an R domain (a modified R domain) comprising an amino acid substitution at a specific position as described above. The polypeptide of the present invention may consist of the R domain or may further comprise the T and C domains of CRM197 or the like linked thereto. Therefore, the polypeptide of the present invention may be a modified CRM197 comprising a modified R domain. As shown in the Examples, MBP-R, in which a maltose binding protein (MB?) is linked to a modified. R domain, has inhibitory activity similar to that of the R domain. Since the inhibitory activity is not changed even when another protein is bound to the R domain, the polypeptide of the present invention encompasses a wide range of polypeptides in which another amino acid, peptide, or polypeptide is bound to the N-terminus or C-terminus of the modified R domain. Such a polypeptide can be biotechnologically produced using DNA encoding the polypeptide by a method well known in the art.
Moreover, a known antitumor agent may be chemically bound to the polypeptide of the present invention. Examples of known antitumor agents to be bound to the polypeptide of the present invention include taxol, taxotere, docetaxel, irinotecan, topotecan, doxorubicin, etoposide, CPT-11, camptostar, epothilone, tamoxifen, methoxtrexate, 5FU, temozolomide, cyclophosphamide, SCH66336, R115777, L778, 123, BMS214662, Iressa, Tarceva, antibodies to EGF receptor (EGFR), Gleevec, intron, ara-C, Adriamycin, Cytoxan, gemcitabine, uracil mustard, chlormethine, ifosfamide, melphalan, chlorambucil, pipobroman, triethylenemelamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, pentostatin, vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, epirubicin, idarubicin, mithramycin, deoxycoformycin, mitomycin-C, and the like.
The antitumor agent of the present invention is effective for treatment of cancer, such as ovarian cancer, breast cancer, prostate cancer, stomach cancer, lung cancer, colorectal cancer, and pancreatic cancer.
The anti-cancer agent of the present invention is effective for treatment of cancer in which the expression of HB-EGF is especially enhanced among growth factors of the EGF family.
The antitumor agent or anti-cancer agent of the present. invention can be formulated from the above active ingredient, or can be formulated by coming the ingredient with a pharmaceutically acceptable pharmaceutical carrier. The pharmaceutical carrier refers to a known pharmaceutically acceptable solid or liquid carrier that is pharmacologically inert and that is useful for formulation for administration of a pharmaceutically active ingredient.
The above therapeutic agent can be administered orally or parenterally (e.g., intravenous, intramuscular, intraperitoneal, subcutaneous or intradermal injection, intrarectal administration, transmucosal administration, or administration via the respiratory tract).
Examples of the dosage form of the pharmaceutical composition suitable for oral administration include, but are not limited to, tablets, granules, capsules, powders, solutions, suspensions, syrups, and the like. Examples of the dosage form of the pharmaceutical composition suitable for parenteral administration include, but are not limited to, injections, drops, suppositories, percutaneous absorbents, and the like.
Types of pharmaceutical additives used for production of the therapeutic agent are not particularly limited and can be suitably selected by those skilled in the art. Examples of additives that can be used include excipients, disintegrators or disintegration aids, binders, lubricants, coating agents, bases, solubilizers or solubilizing agents, dispersants, suspending agents, emulsifiers, buffers, antioxidants, preservatives, tonicity adjusting agents, pH adjusters, solubilizers, stabilizers, and the like. Specific individual ingredients used for these purposes are well known to those skilled in the art.
Examples of pharmaceutical additives that can be used for production of the preparation for oral administration include excipients, such as glucose, lactose, D-mannitol, starch, and crystalline cellulose; disintegrators or disintegration aids, such as carboxymethylcellulose, starch, and carboxymethylcellulose calcium; binders, such as hydroxypropylcellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, and gelatin; lubricants, such as magnesium stearate and talc; coating agents, such as hydroxypropyl methylcellulose, sucrose, polyethylene glycol and titanium oxide; and bases, such as Vaseline, liquid paraffin, polyethylene glycol, gelatin, kaolin, glycerin, purified water, and hard fat.
Examples of pharmaceutical additives that can be used for production of the preparation for injection or infusion. include solubilizers or solubilizing agents that can constitute aqueous injections or injections that are dissolved at the time of use, such as distilled water for injection, physiological saline, and propylene glycol; tonicity adjusting agents, such as glucose, sodium chloride, D-mannitol, and glycerin; pH adjusters, such as inorganic acids, organic acids, inorganic bases, and organic bases; and the like.
Although the amount of the active ingredient contained in the therapeutc agent of the present invention varies depending on the dosage form or administration route of the therapeutic agent and cannot unconditionally be defined, it can be generally selected and determined as appropriate from the range of about 0.0001% to 70% in the final preparation.
The therapeutic agent of the present invention can be administered to mammals, including human beings, in particular human beings, as a subject.
Although the dose of the therapeutic agent of the present invention should be appropriately increased or reduced. depending on conditions, such as the age, sex, body weight, and symptoms of a patient and the route of administration, it is such that the amount of the active ingredient per day per adult is preferably about 1 μg to 100 mg, more preferably about 10 μg to 10 mg, and even more preferably about 100 μg to 5 mg. The pharmaceutical in the above dose may be administered in one to several portions a day. The pharmaceutical may be administered once a week over a period of 6 to 8 weeks, may be administered every other day over a period of 2 to 3 weeks, or may be administered daily for 10 to 14 days.
The present invention includes a method for treating a tumor, comprising administering an effective amount of the polypeptide of the present invention to a subject. The present invention also includes use of the polypeptide of the present invention for the production of an antitumor agent.
Examples are given below to illustrate the present invention in more detail; however, the present invention is not limited to these Examples.
Recombinant HB-EGF and TGF-α were obtained from R&D Systems (MN, U.S.A.). C-terminal His-tagged HB-EGF lacking the heparin-binding domain was purified as described in the document (Takazaki, R., et al., J Biol Chem, 2004. 279 (45): p. 47335-43).
DER cells were established and maintained by introducing exogenous human EGFR cDNA into bone marrow-derived lymphoblastic 32D cells as previously reported. (Iwamoto, R., K. Handa, and E. Mekada, J Biol Chem, 1999. 274 (36): p. 25906-12.). Buffalo rat liver (BRL) cells and BRL cells (BRLH) that express exogenous human HB-EGF were established and maintained as previously reported (Mizushima, H., et al., J Cell Sci, 2009. 122 (Pt 23): p. 4277-86).
The cDNA of the entire R domain (residues 380-535) amplified by PCR was inserted into the BamHI-EcoRI site of a pGEX-3 vector (GE Healthcare) to transform E. coli JM109. A single colony was inoculated into 40 mL of an LB medium containing 50 μg/mL ampicillin (LB-amp) and grown at 37° C. overnight. The pre-culture medium was inoculated into 500 mL of fresh LB-amp and grown at 37° C. until it reached the bacterial logarithmic growth phase. 0.4 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) was added thereto and cultured at 37° C. for 2 hours. The culture medium was centrifuged to collect E. coli cells. The E. coli cells were washed with solution A (20 mM Tris-HCl, pH of 8.0, 30 mM NaCl, 10 mM EDTA) containing 0.2 mM phenylmethylsulfonyl fluoride (PMSF), collected again by centrifugation, and lysed with solution. A containing lysozyme (40 μg/mL) on ice for 1 hour. Triton-X100 (0.53%) and NaCl (100 mM) were added to the bacterial lysate, followed by incubation on ice for 15 minutes and sonication in the presence of 0.2 mM PMSF for 20 seconds (twice on ice). Centrifugation was performed, and the supernatant was incubated with a glutathione sepharose 4B gel (GE Healthcare) at 4° C. overnight. The gel was washed with solution A, and bound protein was eluted with an elution buffer (100 mM Tris-HCl, pH of 8.0, 6 mM glutathione).
The cDNA of the R domain was cloned into the XhoI-EcoRI site of a pThioHis vector (Invitrogen, CA, U.S.A.) to transform E. coli JM109. The ThioHis-fusion protein was purified using an His-Patch ThioFusion™ expression system. (Invitrogen) according to the manufacturer's instructions.
Maltose Binding Protein (MBP)-Fusion R domain
The cDNA of R domain was cloned into the BamHI-PstI site of a pMAL-p2 vector (New England BioLabs Inc., MA, U.S.A) to transform E. coli JM109. The primers used for PCR were as follows (the restriction enzyme sites for cloning are underlined):
Further, to separate the R domain from MBP, an oligonucleotide encoding the PreSicission Protease (GE Healthcare) recognition sequence (LEVLFQ/GP) was inserted into the BamHI site of the pMAL-p2 vector.
A single colony was inoculated into 40 mL of LB-amp and grown at 37° C. overnight. The pre-culture was inoculated into 500 mL of fresh LB-amp and cultured at 37° C. until it reached the logarithmic growth phase. 1 mM IPTG was further added, followed by culturing at 37° C. for 3 hours. The bacteria were collected by centrifugation and washed with buffer B (20 mM HEPES, pH of 7.3, 150 mM NaCl). The bacteria were collected again by centrifugation, resuspended in buffer B, and disrupted by sonication. The bacterial lysate was clarified by centrifugation, and the supernatant was mixed with an amylose resin (New England BioLabs) at 4° C. overnight. The resin was washed with buffer B, and bound protein was eluted with buffer B containing 100 mM maltose. Release of the R domain from the fusion protein was carried out by incubation with PreSicission Protease. The released MBP and PreSicission Protease were removed by incubation with the amylose resin and glutathione sepharose 4B.
MBP-R domain mutants were constructed by site-directed mutagenesis using PCR. The oligonucleotides used are listed in Table 1. Plasmids encoding the MBP-R domain mutants were individually introduced. into E. coli JM109 for transformation. The MBP-R. domain mutants were purified by the aforementioned. method.
DER cells (1×104 cells) were cultured in a RPMI1640/10% FCS medium containing 10% fetal bovine serum (FES), recombinant HB-EGF (10 ng/ml), heparin (10 μg/ml), penicillin G (100 U/ml), and streptomycin (100 μg/ml) in the presence or absence of various concentrations of MBP-R domain protein for 40 hours. The concentrations of the MBP-R domain protein were 0.22, 0.67, 2, 6.1, 18.5, 55.5, and 167 μM. The cells were cultured using a 96-well plate (100 μL medium/well). The number of DER cells was measured using Cell Count Reagent SF (Nacalai Tesque, Japan) according to the manufacturer's manual. All experiments were performed three times, and data are represented as mean ±s.d.
Ice-cold bovine Type I collagen (Nitta Gelatin; 3 mg/ml), a reconstitution buffer containing 2.2% (w/v) NaHCO3, 0.2 M HEPES, and 50 mM NaOH; a 10X DMEM-F12 (1:1) medium; and serum-free DMEM in which cells were suspended (5×106 cells/mL) were mixed at an 8:1:1:0.1 ratio, and the mixture was poured into a 24-well dish (0.5 mL/well) as reported previously (Mizushima, H., et al., J Cell Sci, 2009. 122 (Pt 23): p. 4277-86). After incubation at 37° C. for 30 minutes, the collagen gel was covered with 1 mL of DMEM-FBS containing any of CRM197, MBP-R (WT), and MBP-R (mutant), followed by culturing for 1 week. To count the number of cells, incubation with 0.5 ml of 0.5% (w/v) bacterial collagenase (Invitrogen, CA, U.S.A.) was performed at 37° C. in HBS (+) (10 nM HEPES, pH of 7.2, 140 nM NaCl, 4 nM KCl, 1.8 mM CaCl2, and 1 mM MgCl2) until the collagen gel was dissolved, and cells were collected by centrifugation. The cells were fixed and stained with a crystal violet solution (0.1% crystal violet, 0.1 M citric acid), and the number of nuclei was counted under a microscope after vortexing. All experiments were performed three times, and data are represented as mean ±s.d.
Biacore T200 and Sensor Chip NTA (GE Healthcare) were used for this analysis. The coupling constant of HB-EGF and an R domain mutant was measured according to the manufacturer's instructions. Ni2+ was captured at a flow rate of 10 μL/mL on the sensor chip for 60 seconds, and subsequently C-terminal His-tagged recombinant HB-EGF (Δ••-EGF-His) lacking the heparin-binding domain was captured for 180 seconds. Various concentrations of CRM197, MBP-R (WT), or MBP-R (mutant) were allowed to act on the sensor chip at a flow rate of 30 μL/mL for 600 seconds for a binding reaction. Thereafter, dissociation was monitored at a flow rate of 30 μL/mL for 600 seconds. KD and KA values were calculated using Biacore Software (GE Healthcare).
Establishment of C. diphtheriae that Expresses CRM197 Mutant by Means of Triparental Mating
A CRM197 gene and its promoter were obtained from genomic DNA of C. diphtheriae C7hm723 (β197) strain (Eanei, C., T. Uchida, and M. Yoneda, infect immun, 1977. 18 (1): p. 203-9.) by PCR. The primers used are shown below (the restriction enzyme sites for cloning are underlined):
The amplified DNA was inserted into the BglII-NotI site of a pK-PIM vector (Oram, M., Woolston, J. E., Jacobson, A. D. Holmes, R. K. & Oram, D. M. Bacteriophage-based vectors for site-specific insertion of DNA in the chromosome of Corynebacteria Gene 391, 53-62, (2007).). A CRM197 (R460H) mutant was constructed by site-directed mutagenesis using pK-PIM/CRM197. DH10B/pK-PIM, HB101/prk2013, and C. diphtheriae were individually pre-cultured at 37° C. overnight and mixed at a ratio of DH10B:HB101:C. diphtheriaeC7 (−)=1:1:8. The bacterial mixture pellet, was added to a Brain. Heart Infusion (BHI) agar plate and incubated at 30° C. The bacterial mixture was diluted with a BHI medium and incubated in a complex BHI agar plate containing nalidixic acid (20 μg/mL) and kanamycin (5 μg/mL) at 30° C. for 16 hours. Further, an isolated colony was cultured in a BHI medium containing 20 μg/mL of nalidixic acid and 5 μg/mL of kanamycin to obtain Corynebacterium diphtheriae into which pK-PIM was incorporated.
Preparation and Purification of CRM197 and CRM197 mutant.
CRM197 and a CRM197 mutant were prepared and purified as previously reported (Uchida, T., A. M. Pappenheimer, Jr., and R. Greany, J Biol Chem, 1973. 248 (11): p. 3838-3844).
Unless otherwise indicated, data were represented as mean ±standard deviation. A statistically significant difference was evaluated using Student's t-test. A value of p<0.05 was considered significant.
Preparation of Recombinant R Domains of CRM197 and HB-EGF-inhibitory activity
R domains of CRM197 fused to three kinds of expression-purification tags (GST, TRX, and MBP) were constructed and expressed in Escherichia coli. These fusion proteins, called GST-R (WT), TRX-R (WT), and MBP-R (WT), were prepared and purified according to a standard procedure or the manufacturer's instructions. Since the MBP-fusion protein had the highest purity and stablity among the constructed fusion proteins, the MBP-R domain was used for further investigations.
First, it was investigated whether MBP-R (WT) suppresses HB-EGF-dependent cell growth using a DER cell growth assay system. DER cells are derived from IL-3-dependent 32D cells, stably express human EGF receptor (EGFR), and can grow in EGFR ligand-containing media. DER cells show EGFR-ligand-dependent cell growth in the absence of IL-3. Therefore, DER cell growth assay in the presence of HB-EGF allows detection of HB-EGF-inhibitory activity in a test sample in an HB-EGF-specific manner. MBP-R (WT) suppressed the growth of DER cells in a dose-dependent manner (
To evaluate the inhibitory activity of R domain mutants against HB-EGF cell growth activity, DER cells were cultured with a certain amount of HB-EGF in the presence of various concentrations of the R domain mutant proteins. Representative data are shown in
Six R domain mutant proteins showed inhibitory activity higher than that of MBP-R (WT). The ID50 value of each mutant compared with CRM197 was as follows: CRM197, 1.2 nM; MBP-R (R460H), 2.5 nM; MBP-R (H391K), 3.1 nM; MBP-R (R472K), 3.2 nM; MBP-R (D507N), 4.5 nM; MBP-R (H520K), 6.0 nM; MBP-R (V468T), 6.2 nM; MBP-R (WT), 7.9 nM.
Next, a mutant having multiple mutations (MBP-R (G466D/D467A/V468T)) was prepared and its inhibitory activity was also investigated.
To investigate whether the inhibitory activity of these R domain mutants is specific to HB-EGF, DER cells were cultured in the presence of TGF-α and the R domain mutants. None of these mutants affected the growth of DER cells (
The effect of HB-EGF on cell growth is notably exerted particularly in 3D culture conditions (Mizushima, H., et al., J Cell Sci, 2009. 122 (Pt 23): p. 4277-86.). Thus, the present inventor cultured BRL cells in 3D culture conditions using a collagen gel to investigate the inhibitory activity of four R domain mutants against the HB-EGF-dependent growth of BRL cells. The four R domain mutants, i.e., MBP-R (H391K), MBP-R (G466D/D467A/V468T), MBP-R (R460H), and MBP-R (R472K), more effectively suppressed recombinant HB-EGF-induced BRL cell growth than MBP-R (WT) (
To investigate whether four R domain mutants possess increased affinity for HB-EGF compared with the wild-type R domain, the affinity constants of the mutants were determined using Biacore according to the manufacturer's instructions. The binding of each MBP-R domain protein to recombinant HB-EGF captured on the sensor tips was measured to calculate the affinity constants KA from the association rate constants and the dissociation rate constants. The affinity constant values of the proteins were as follows: CRM197, 9.22×108 M−1; MBP-R (R460H), 6.09×108 M−1; MBP-R (G466D/D467A/V468T), 4.44×108M−1; MBP-R (R472K), 4.42×108 M−1; MBP-R (H391K), 3.17×108 M−1; MBP-R (WT), 2.99×108 M−1 (Table 4). The affinity constant values almost correlate with the ID50 values. These results show that the increased affinity for HB-EGF contributes to the inhibitory activity of the four mutants.
MBP-R (WT) exhibits cell growth inhibitory activity lower than that of full length CRM197, suggesting that the overall molecular structure is required to show an absolute inhibitory effect. Thus, the present inventor reconstructed and prepared full length CRM197 having R460H mutation in the C. diphtheriae strain as described above and compared its inhibitory activity with that of CRM197. CRM197 (R460H) inhibited the HB-EGF-dependent growth of DER cells more effectively than the wild-type CRM197 (
To investigate whether the affinity constant of CRM197 is improved by the R460H mutation as observed in the MBP-R domain mutants, the affinity constants KA of CPM197 and CPM197 (P4 60H) were compared using Biacore. The affinity constants KA of CRM197 and CRM197 (R460H) were 9.80×108M−1 and 1.63×109M−1, respectively (Table 5). These results show that the inhibitory activity of CRM197 against HB-EGF is increased by the mutation.
Complementary oligonucleotides of the Fw primers used were used as reverse primers.
where 5 μM of CRM197 or an MBP mutant was added was indicated as a percentage (%), based on the number of cells in the case where neither CRM197 nor an MBP mutant was added being 100%.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2014-008675 | Jan 2014 | JP | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/JP2014/076945 | 10/8/2014 | WO | 00 |
